Influence of vitrectomyon the progressionof wet age related macular degeneration

Abstract

Purpose. To study the effects of vitrectomy on the course of wet age-related macular degeneration (AMD). Materials and methods. 99 patients (99 eyes) with wet AMD associated with vitreo-macular adhesion or posterior hyaloid traction were included in the study. During the first 6 months, all patients received anti-VEGF treatment according to a PRN regimen. Then, they were divided into two groups: in 45 patients vitrectomy was performed and 54 patients did not receive surgical treatment. The follow-up period duration was one year. Results. At the beginning of the study, visual acuity was 0.27 ± 0.17 in the control group, and 0.17 ± 0.15 in the treatment group. Most prominent differences in visual acuity between the two groups were observed during the first 6 months (visual acuity in the treatment group before surgery was 0.12 ± 0.1) (p < 0.01 and p < 0.001), at the same time during the following 6 follow-up months, this difference decreased (p < 0.05 and p < 0.01). 1 year from the study start, visual acuity in the control group was 0.24 ± 0.17, and 0.17 ± 0.13 in the treatment one. Conclusions. Vitrectomy surgery in patients with wet AMD in association with vitreo-macular adhesion or posterior hyaloid traction does not exacerbate the disease course, stabilizes visual functions and improves the quality of life.

Keywords

age-related macular degeneration / vitrectomy / vitreous / vitreo-macular traction / quality of life

References

[1] Астахов Ю. С., Лисочкина А. Б., Шадричев Ф. Е. Возрастная ма кулярная дегенерация. Клинические рекомендации. Офтальмология/Под ред. Мошетовой Л. К., Нестерова А. П., Егорова Е. А. М.: ГЭОТАР-Медиа. 2006; 164-188.

[2] Bindewald A., Bird A. C., Fitzke F. W. Classification of Fundus Autofluorescence Patterns in Early Age-Related Macular Disease. Invest. Ophthalmol. Vis. Sci. 2005; 46: 3309-3314.

[3] Bird A. C., Bressler N. M., Bressler S. B. An international classifica tion and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmоl. 1995; 39: 367-374.

[4] Green-Simms A. E., Bakri S. J. Vitreomacular traction and age-rela ted macular degeneration. Semin Ophthalmol. 2011; 26 (3): 137-138.

[5] Hyman L. G., Lilienfeld A. M., Ferris F. L. Senile macular degeneration: a case-control study. Am. J. Epidemiol. 1983; 118: 213-227.

[6] Klein R., Klein B. E., Knudtson M. D. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology2007; 114: 253-262.

[7] Klein R., Klein B. E., Linton K. L. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992; 99: 933-943.

[8] Krebs I., Brannath W., Glittenberg C. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am. J. Ophthalmol. 2007; 144 (5): 741-746.

[9] Lee S.J., Koh H.J. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011;118(1):101-110.

[10] Ondes F., Yilmaz G., Acar M. A. Role of the vitreous in age-related macular degeneration. JpnJ Ophthalmol. 2000; 44: 91-93.

[11] Schulze S., Hoerle S., Mennel S., Kroll P. Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol. 2008; 86 (5): 470-481.

[12] Spaide R. F., Armstrong D., Brown R. Continuing medical education rewiew: choroidal neovascularization in age-related macular degeneration - what is the cause. Retina. 2003; 23: 595-614.

[13] Stefánsson E., Geirsdóttir A., Sigurdsson H. Metabolic physiology in age related macular degeneration. Prog. Retin. Eye Res. 2011; 30: 72-80.

RIGHTS & PERMISSIONS

Astakhov Y.S., Shaar G.B., Dal’ N.Y.